Manufacturers

Pharma in the field: Barrett's story

Manufacturers

Podcast: How 2023 will shape the US Biosimilar space for 2024 and beyond

Manufacturers

Work worth doing: Innovative field solutions

Manufacturers

Essential skills for outsourced field solutions teams

Manufacturers

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

Manufacturers

Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

HTA Quarterly | Fall 2023

Manufacturers

Only 17 months until the implementation of the new EU JCA—Latest developments and remaining uncertainties

Manufacturers

The cures conundrum: The importance of getting value assessment right for transformational therapies

Manufacturers

VPAS—Where next?

Manufacturers

Top 4 current economic challenges faced by biopharma companies

Latest Policy Trends Webinar On Demand

Manufacturers

Case study: Driving robust healthcare decision maker engagement

Manufacturers

Empower your people and brand with biopharma learning solutions

Manufacturers

On-demand webinar: The EU JCA process: Opportunities and challenges in bringing innovative medicines to patients in Europe

Manufacturers

Formulary Fuel Webinar Series

Reimbursement considerations for home infusions

Copay accumulator adjustment programs significantly increase patient financial burden

Recap ISPOR 2023: Our expertise in action

Issue Brief: Assessing the impact of formulary exclusion on healthcare costs and outcomes for patients on therapy for certain chronic conditions

Manufacturers

Q&A: The evolution of the cell and gene therapy field

Manufacturers

Recap Asembia 2023: Our impactful contributions to the premier specialty pharmacy conference

Payer use of US value assessment tools: New insights and implications for our evolving healthcare system

10 years of HTA Quarterly: Looking back to see how far we’ve come

Reflections on an interview with a ghost

Project Orbis: A three-year review

Manufacturers

Three opportunities and three challenges in the cell and gene therapy market

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

Optimize your pre-approval information exchange strategy

Manufacturers

How to forge stronger working relationships with payers

Manufacturers

Yes, you can commercialize on your own—even if you're an emerging biopharma

Webinar: IRA Update: Key considerations for 2023

Medicare cannot age in place: A diversifying population requires policy evolution

Fifty shades of… innovativeness: The Italian job

Webinar slides: Breaking Down the Complexities of Product Evaluation in the Digital Era

Biosimilar success in the US market landscape requires a holistic approach

Manufacturers

The essential guide to drug commercialization

Navigating the road to successful biosimilar uptake in Europe – Still some way to go?

Cancer disproportionately impacts adults living in rural areas

Manufacturers

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

Using the right tools to improve the formulary review process

Smoothing the access road to treatment for Medicare Part D beneficiaries

Manufacturers

Three questions to ask about your market access partner

Manufacturers

Acceleration of innovation in healthcare delivery

Manufacturers

The time is right for commercializing prescription digital therapeutics

Manufacturers

HTA Quarterly | Summer 2023

How to get earlier market access in the UK: Use the Innovative Medicines Fund

Has mandatory HTA improved access to new medicine in Denmark? Learnings from the first 5 years with the Danish Medicines Council

I-R-A or Eye-Ra - however you frame it, the new US drug pricing law is sure to have a significant impact on the global pharmaceutical market

Manufacturers

Branding: The difference between good and great patient assistance programs

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

HTA Quarterly | Winter 2022

Webinar: the evolution of value assessment in the US: considerations and controversies

The path forward for innovative contracts: A survey of US healthcare payers

Manufacturers

Improve outcomes and reduce costs for emerging therapies

Manufacturers

On-demand webinar: You’ve created a good patient support program, now make it great

Closing the Gaps in Pre-Approval Information Exchange to Accelerate Product Success and Patient Access

Manufacturers

HTA Quarterly | Fall 2022

The new EU regulation on health technology assessment: Major change or minor adjustment?

Did health economics fail us during the COVID-19 pandemic?

Upcoming cost-containing measures in Germany—How will they affect the biopharmaceutical industry?

Manufacturers

Market access abroad: Three reasons why early planning is critical for HTA countries

Manufacturers

Innovative agreements: Exploring alternative payment models

Manufacturers

Culture, people, and an investment in innovation set AmerisourceBergen apart

Manufacturers

Navigating reimbursement and access challenges for novel cell and gene therapies

Manufacturers

Why FormularyDecisions® is the right choice for enterprise biopharma payer engagement 

Alopecia areata: A global perspective of a disease that extends beyond hair loss

The biosimilars marketplace: Part one

Manufacturers

Webinar slides: Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies

Research poster: The current impact of ICER assessments on payer decision making

Skyrocketing growth in PBM formulary exclusions continues to raise concerns about patient access

Do fair prices lead to fair access? Supporting access with a comprehensive value proposition to bridge the gap

Orphan drugs: trapped in the lock? A review of the lock system in the Netherlands

The answer to the ultimate question of life, the universe, and everything? New NICE HTA manuals

HTA Quarterly | Summer 2022

Medicaid Best Price and Its Implications on Cell and Gene Therapy Products

Manufacturers

Differentiate your product with FormularyDecisions®

Manufacturers

Six insights driving the evolution of FormularyDecisions®

Webinar: Debunking common PIE misperceptions to enhance your PIE strategy and tactics

The drug reimbursement environment in Canada: An overview

HTA Quarterly | Spring 2022

Joint clinical assessment in the EU: Pan-European HTA for drugs and medical devices will become reality 

The UK Innovative Licensing and Access Pathway—A new paradigm in market access

Accelerated approval not accelerated access: Clinical trials required for coverage of Alzheimer's treatments

Preparing for 2023: piloting copay assistance through strong headwinds

Manufacturers

Webinar: Bridging the HCEI Divide – Insights on an Effective Healthcare Economic Information (HCEI) Exchange

The impact of the Build Back Better Act (BBBA) on rare disease innovation

HTA Quarterly | Winter 2021

Is NICE becoming nicer?

Evidence generation and approval of digital health applications in Germany

340B – A missed opportunity to address those that are medically underserved

Telehealth through the lens of value-based care in the US

ASCVD needs innovation

Manufacturers

Building your field reimbursement and access team: The translational experience and skills that matter most

Health disparities and health technology assessment: Current value assessment frameworks fall short

HTA Quarterly | Fall 2021

Gaining real-world oncology insights from engagement of key opinion leaders through virtual and live solutions

Elucidating ICER’s methodologies for Unsupported Price Increase assessments  

Equity considerations in US value assessment: Opportunities ahead

Affordability is about more than drug prices

Manufacturers

What manufacturers need to know about reimbursement and patient support for cell and gene therapies

Manufacturers

Navigating the payer landscape for digital therapeutics

Manufacturers

Webinar: the rise of digital information dissemination: communication trends in managed care

Copay accumulators and the impact on patients

Update: The impact of obesity on COVID-19 outcomes of hospitalizations and mortality

Manufacturers

Work worth doing: FormularyDecisions

On-demand webinar: Alopecia areata reliably effective treatment is on the horizon

Alopecia Areata: A disease that extends beyond physical manifestations

Predicting the pandemic: COVID-19 modeling rights and wrongs

HTA Quarterly | Summer 2021

Assessing the value of vaccines: Considerations from the HTA perspective

ICER seeks to improve healthcare decision making with new customizable analytic tools 

Are US payers getting to grips with cost-effectiveness analysis?

Manufacturers

Ebook: Strategic partnerships for unlocking product potential

Manufacturers

Buy-and-bill vs. self-administered: Field services remove barriers across access points

Manufacturers

Strategies for addressing copay accumulators: What manufacturers need to know

A comparison of the Innovation and Value Initiative’s Open-Source Value Project and the Institute for Clinical and Economic Review’s value assessment framework

Outlook for advanced therapy medicinal product price negotiations in Germany

Real-world evidence in United States regulatory decisions 

HTA Quarterly | Spring 2021

Manufacturers

Webinar: uptake or heartbreak with biosimilars? Progress and perspectives

Manufacturers

Checklist: Four things to look for in a field services partner

Manufacturers

Launching field services in the midst of COVID-19

The impact of obesity on COVID-19 outcomes of hospitalizations and mortality

Patient forward: comparing ICER and PCORI use of patient feedback

Manufacturers

Case study: an innovative field reimbursement program expands patient access

Manufacturers

Evaluating the modern field reimbursement and access program: key considerations

Manufacturers

Pharma in the field: Heather's story

Manufacturers

Webinar: the growing utilization of copay accumulator programs

It’s the Healthcare of the Future: Telehealth Trends Beyond 2020

Patient-Centered Cost Outcomes—Addressing a Gap in Value Assessment

New Copay Accumulator Policy Could Ignite Payer Trend on Medical Benefit Products

Manufacturers

Pharma in the field: Ashley's story

Manufacturers

Pharma in the field: Tierra's story

HTA Quarterly | Winter 2020

Ushering in a New Era of Antibiotic Innovation With a Netflix-Style Subscription Payment Model

HTA and Affordability for Innovative Therapies in Germany, Perspectives on Advanced Therapy Medicinal Product (ATMP) Pathway

ICER’s Growing Influence on Payer Decision Making: The Impact of ICER Assessments on Market Dynamics and Patient Access

Manufacturers

Ebook: Virtual drug commercialization

AMCP Nexus 2020 Virtual Recap

Let's Ditch 2020 and Plan for 2021: Election What-Ifs

Manufacturers

PAP 2020 panel recap: Navigating COVID-19

Size Doesn't Matter: A Small Biotech Plays Big with Payer Engagement

Impact of First Dollar Coverage for Insulin

COVID-19 Drives Through the American Heartland

Manufacturers

Is a contact-free clinical trial possible?

Manufacturers

Is your PIE incomplete?

Webinar: 5 Years of ICER - Insights and Impact on Payers

Skyrocketing Growth in PBM Formulary Exclusions Raises Concerns About Patient Access

Case study: Gaining payer attention through digital innovation

Manufacturers

Rethink field services: Three myths keeping access barriers in front of your product

Manufacturers

Solving access, reimbursement, and PAP awareness problems

Medicaid's Proposed “Line Extension” Redefinition Imperils Innovation and Patient Access

Incorporating the Patient Voice in Value Assessments: The Evolution of ICER’s Approach to Patient Engagement

Feature Article: 20 Years After the National Health Insurance Act, HTA Policy Changes Reshape Market Access in South Korea

Market Trends and Updates: New Pharmaceutical Policies Have Dramatically Changed the Landscape in China

Therapeutic Spotlight: New Evidence Brings Cautious Optimism to Alzheimer’s Disease Treatment

Webinar | Navigating COVID-19: Simplifying the Path to Better Patient Outcomes

HTA Quarterly | Fall 2020

Manufacturers

Pharma in the field: Sales reps vs. reimbursement and access specialists

Patient Support in the Time of COVID-19: Five Ways to Adapt

Potential Access Implications of a National Formulary in Part D

The Heart of the Value Story

Manufacturers

The Future of Payer Engagement: How Pharma Can Break Through

Now Available: Out in Front Effective Pre-approval Communication with Payers Webinar Slides

Manufacturers

The Value of Virtual: How Remote Workshops Can Keep Market Access Efforts Moving

HTA Quarterly | Summer 2020

Regulatory and Market Access Impact in Europe of the Recent Medical Software Makers Guidance

Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball

The Era of mHealth: A Global Perspective

Webinar: Navigating Pre-approval Information Exchange (PIE) and the AMCP Format for Formulary Submissions, Version 4.1

Let’s Get Digital: Moving the Physical to the Virtual Visit

Manufacturers

Distant But Engaged: Transitioning to Virtual Training

Manufacturers

Webinar: Patient Assistance in the Wake of COVID19

Addressing an Evidentiary Gap With Real-World Prospective Studies

The Potential Impact of Pharmaceutical and Non-Pharmaceutical Interventions to Mitigate the COVID-19 Crisis in the United States: A Model-Based Analysis

Manufacturers

How COVID-19 Will Impact Patient Support

Impact of COVID-19 Pandemic on Patient Access Programs

How the Adoption of Health Technology Assessment Is Changing the Healthcare Landscape of India

HTA Quarterly | Spring 2020

A Tale of 2 Frameworks: Impact of ICER and NICE Updates on Future HTAs and Market Access

Integration of Patient-Reported Outcomes (PROs) and the Patient Voice: A Review of 6 Health Technology Assessment (HTA) Agencies

Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments

Gene Therapies Pave the Way to a Potential Cure for Sickle Cell Disease

Manufacturers

Video: Removing Barriers for Biosimilars

Making Part D Access Affordable: Revising the Prescription Drug Benefit

Manufacturers

Mind the (Evidence) Gap

The Impact of Step-Therapy Policies on Patients

Effectively Communicating Pipeline Information to Drive Payers Attention

Can We Afford Curative Therapies Without Sharing Risks? Perspectives on HTA and Affordability in This New Innovation Era

State-based Analysis: ICER-based Formularies Could Upend Access to Current Treatments in Medicaid

Market Access for Cell and Gene Therapies in Key European Countries

FINOSE Finishes 2 Joint HTAs in the Nordics

HTA Quarterly | Fall 2019

The Cost of Cures: What Does Zolgensma Teach Us About the Use of Cost-Effectiveness Assessments?

Manufacturers

Biosimilars: Launch Insights From the Field

A Comprehensive Field Reimbursement Training Program Expands Patient Access

HTA Quarterly | Summer 2019

Review of HTA Frameworks and Decisions for Next-Generation Sequencing in Precision Oncology

Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?

Rise of Complex Technologies and a Challenging Reimbursement Landscape: How a Forward-Looking Indirect Treatment Comparison Feasibility Study Can Help Navigate Market Access

Healthcare System Changes in France

Manufacturers

How Digital Innovation Drives Improved Market Access Strategies

Manufacturers

Copay Accumulators: Are Your Patients Really at Risk?

Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions

HTA Quarterly | Spring 2019

Can Patients Help Influence Drug Development? Where are We with Respect to Patient Input on Early Scientific Advice in North America and Europe?

Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model

The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability

Manufacturers

Managing the Growing Expansion of Copay Accumulators

Original Report: Impact Analysis of ICER Formulary Implementation in Medicaid

Assessment of Emerging Therapies for Cystic Fibrosis

Diabetes and the Growing Investment in Drugs, Devices, and Diagnostics 

MCDA: Too Much Talk, Too Little Progress?

HTA Quarterly | Winter 2019

Manufacturers

Medicare Part B: Do Providers Choose Treatment Based on Payment?

Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries

Valuing CAR-T Therapies: Facing New Challenges, Fulfilling the Potential

Wearing Your Data: A Global Perspective

Catalonia: Understanding Market Access Within an Autonomous Region in Spain

Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments

Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?

Japan’s Ongoing Shift From a Traditional Reimbursement Assessment to a Novel Cost-Effectiveness Submission Requirement

Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia

Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division

HTA Quarterly | Fall 2018

HTA Quarterly | Late Summer 2018

Emerging Trends in PBM Restrictions on Commercial Copay Assistance

Manufacturers

How Policy Impacts Patient Support

Portugal: A Glimpse into Europe's Future in an Era of Austerity and HTA Reform?

Connected Health: The Next Healthcare Frontier

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Top Trends in Health Policy in Canada: Insights from InnomarLive

The European Medicines Agency to Find a New Home After Brexit

Are Emerging Value Frameworks a Path to Implementing Value-Based Pricing?

HTA Quarterly | Summer 2018

Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries

State-Led: The Push for Transparency in Drug Pricing

Manufacturers

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Manufacturers

Seeing the Value and Transparency of Medicare Part B

HTA Quarterly Spring 2018

Achieving Market Access Across the Globe for CGTs

Payer Tactics to Manage Commercial Copay Assistance Gaining Traction

Implementing Coverage With Evidence Development

Recent Trends in Oncology Appraisal Decisions: NICE vs. SMC

Xcenda Examines the Impact of the Tax Cuts and Jobs Act on the Life Science Sector

2018 Trends-Leaning Into the Chaos

Xcenda Collaborates with Family Reach on Critical Issue - Cancer-Related Financial Toxicity

Manufacturers

What Do Payers Think About Digital Health Technologies

HTA Quarterly Late Summer 2017

Medical Nutritional Therapy: Achieving Reimbursement Across the Globe for Unique Non-drug Therapy Options

Brazil—The Largest Market in Latin America

Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine

HTA Quarterly | Summer 2017

Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers

Hearing the Patient Voice: How 4 Countries are Utilizing Patient Input

Understanding the Columbian Health Care Market

HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients

Biosimilar Coding—Could There Be Billions in Hidden Savings?

Payer Perceptions and Utilization of ICER Value Assessment Framework

FDAMA 114 and the 21st Century Cures Act

HTA Quarterly | Spring 2017

When the Outcome of an Appraisal Is Not NICE: An Overview of the Appeal Process

Navigating Coverage and Reimbursement for Immunotherapy in Oncology

Revisiting the Familiar: Time to Re-evaluate the GVD?

Xcenda Conducts Unique Research on Air Medical Services Costs

Multiple Myeloma: Rapidly Advancing Therapeutic Landscape

HTA Quarterly | Winter 2017

Indication-specific Pricing: What should manufacturers expect in key markets

HTA Quarterly | Fall 2016

Singapore: Key Insights Into One of the World’s Most Efficient Healthcare Systems

Psoriasis and Psoriatic Arthritis: Harnessing the Potential of Targeted Therapies

Rapid Access in the US, UK, and France

Analyzing the impact of Medicare Part D for Oncology Patients

Part B Drug Payment Change: Understanding the Implications for Pharma

Payer Contact in a “Contactless” World: Achieving Early Engagement